Invests in
Sectors:
Min Investment:
$250,000.00Max Investment:
$20,000,000.00Target Investment:
$10,000,000.00
Skills
Education
- SU
Lists including Nina
Investments
Actio Biosciences
Total Funding: $55M
Rondo Therapeutics
Total Funding: $67M
Vineti
Total Funding: $100M
Dauntless Pharmaceuticals
Total Funding: $37M
Welltok
Total Funding: $240M
Eiger BioPharmaceuticals
Total Funding: $37M
TESARO
Total Funding: $320M
Tizona Therapeutics
Total Funding: $43M
Cidara Therapeutics
Total Funding: $32M
Ocera Therapeutics
Total Funding: $40M
Work Experience
Partner
2024
Providing angel investment and strategic advice to life science entrepreneurs and organizations with emphasis on business planning, organizational development and fundraising. Leveraging 25+ years of industry experience and deep network to help biotech companies, investors and non-profits advance research and deliver new medicines for patients.
2015
General Partner
2015
Venture capital investing. New company formation. Partnering with entrepreneurs.
2023
Board Member
2023
2023
Board Member
2023
Proxygen is focused on the discovery and development of molecular glue degraders against targets of unmet medical need across various indications. While advancing its internal programs towards clinical development, the company also maintains strategic partnerships to co-create synergies along the drug development pipeline. With its headquarters and laboratory operations in Vienna, Austria, Proxygen employs talent both locally and remotely all over Europe. Partnered with Boehringer Ingelheim and Merck KGaA.
2022
Board Member
2022
Rondo Therapeutics is a biopharmaceutical company exploring new frontiers in cancer therapy. Rondo is committed to advancing the field of immuno-oncology, with a focus on treating solid tumors that fail to respond to current therapies. Our solution is to create a new class of bispecific antibodies that safely engage the immune system to initiate and sustain a robust anti-tumor response and overcome the suppressive tumor microenvironment.
Board Member
2020
A clinical-stage cancer immunotherapy company developing TTX-030, a first-in-class anti-CD39 antibody
Board Member
2016
Board Member
2024
Board Member
2024
2018
Health Innovators' Fellow
2018
The Health Innovators Fellowship’s mission is to develop a community of energized, values-driven leaders committed to finding viable solutions to confront U.S. health care’s problems. The Fellowship offers high-performing professionals a unique experience—the ability to connect with and learn from a diverse group of peers with whom they wouldn’t ordinarily interact while refining their own values and charting a course that empowers them to take action in new ways to improve health and health care in America. Fellows come from a wide variety of industries and sectors, ranging from medicine to venture capital to public health and beyond.